Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07247058 · ClinicalTrials.gov registry record · Phase 4
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
A Phase 4 study of Mild Autonomous Cortisol Secretion (MACS), sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07247058: Recruiting Phase 4 study of Mild Autonomous Cortisol Secretion (MACS), sponsored by Johns Hopkins University.
NCT07247058 is a Phase 4 study of Mild Autonomous Cortisol Secretion (MACS) that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07247058, a Phase 4 study of Mild Autonomous Cortisol Secretion (MACS), is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, body composition and bone mineral density than at Baseline. The investigators also assess the effect of Isturisa on quality of life and psychological symptoms in patients with MACS. The investigators hypothesize that treatment with Isturisa will lead to significant improvements in quality-of-life scores and reductions in depression scores compared to Baseline.
Primary Outcome
glycemic control: fasting glucose, HbA1c
Conditions Studied
Interventions
- DRUG Osilodrostat (Isturisa)
Study Locations (1)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-02-02 |
| Est. Completion | 2029-03 |
| Phase | Phase 4 |
What NCT07247058 shows while recruiting
NCT07247058 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Mild Autonomous Cortisol Secretion (MACS) appearing as the primary indexed condition, and to 1 intervention - of which Osilodrostat (Isturisa) is the first listed.
NCT07247058 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07247058 about?
NCT07247058 is a clinical study titled "Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)". To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, bo...
What is the current status of trial NCT07247058?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2026-02-02. Estimated completion is 2029-03.
What conditions does trial NCT07247058 study?
This clinical trial studies the following conditions: Mild Autonomous Cortisol Secretion (MACS).
What interventions are being tested in trial NCT07247058?
The interventions under investigation include: Osilodrostat (Isturisa) (DRUG).
Who is sponsoring clinical trial NCT07247058?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07247058 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Autonomous Cortisol Secretion (MACS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07247058's enrollment target sits among peer trials
10 1941st of 2000 higher than 33 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI